Comment: Why Merck and AstraZeneca may regret turning their back on Britain

Writing in The Times, Professor Geraint Rees (UCL Vice-Provost, Research, Innovation and Global Engagement) explains how the UK’s investment in life sciences and artificial intelligence will support the future of drug discovery, development and delivery.